Form 4: Director Muna Bhanji Increases Stake in Cytokinetics

Director Muna Bhanji acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.

Summary

• Director Muna Bhanji acquired 2,851 shares of common stock at no cost on May 27, 2026.
• The director also received a grant of 4,301 non-qualified stock options with an exercise price of $77.15.
• The options are exercisable starting June 28, 2026, and expire on May 26, 2036.
• Following these transactions, the director's total beneficial ownership of common stock is 26,361 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing standard director compensation and equity alignment rather than a signal of operational change.

Positives

• Increased equity alignment between the director and shareholders.
• Director maintains a significant direct ownership position of 26,361 shares.

Negatives

• None identified.

Risks

• The value of the acquired stock options is dependent on the future market performance of Cytokinetics common stock exceeding the $77.15 exercise price.

Future Outlook

The filing does not provide forward-looking guidance regarding company operations, focusing solely on director equity compensation.

Industry Context

StockSavvy.ai notes that routine equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment with shareholder interests.

Comparison to Industry Standards

• The grant of stock options and restricted stock units to board members is consistent with compensation structures at peer mid-cap biopharmaceutical companies.
• The exercise price of $77.15 reflects the company's current valuation expectations.

Stakeholder Impact

• Positive signal for shareholders as it demonstrates director commitment to the company's long-term equity value.

Next Steps

• Options become exercisable on June 28, 2026.

Key Dates

Keywords

Cytokinetics, CYTK, Insider Trading, Form 4, Director Compensation, Equity Grant